1069 Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with a pelvic mass to an oncology center? | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article info

Diagnostics

1069 Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with a pelvic mass to an oncology center?

Free

Authors

P Lof Netherlands Cancer Institute, Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands PubMed articles Google scholar articles
R Van de Vrie Netherlands Cancer Institute, Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands PubMed articles Google scholar articles
T Korse Netherlands Cancer Institute, Department of Clinical Chemistry, Amsterdam, Netherlands PubMed articles Google scholar articles
M Van Gent Amsterdam University Medical Center, Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands PubMed articles Google scholar articles
S Mom Amsterdam University Medical Center, Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands PubMed articles Google scholar articles
F Rosier-van Dunné Tergooi Hospital , Department of Gynecology, Hilversum, Netherlands PubMed articles Google scholar articles
M Van Baal Flevo Hospital, Department of Gynecology, Almere, Netherlands PubMed articles Google scholar articles
H Verhoeve olvg, Department of Gynecology, Amsterdam, Netherlands PubMed articles Google scholar articles
B Hermsen olvg, Department of Gynecology, Amsterdam, Netherlands PubMed articles Google scholar articles
M Verbruggen Zaans Medical Center, Department of Gynecology, Zaandam, Netherlands PubMed articles Google scholar articles
M Hemelaar Dijklander Hospital, Department of Gynecology, Hoorn, Netherlands PubMed articles Google scholar articles
J Van de Swaluw Dijklander Hospital, Department of Gynecology, Hoorn, Netherlands PubMed articles Google scholar articles
H Knipscheer Spaarne Hospital, Department of Gynecology, Haarlem, Netherlands PubMed articles Google scholar articles
J Huirne Amsterdam University Medical Center, Department of Gynecology, Amsterdam, Netherlands PubMed articles Google scholar articles
S Westenberg Noordwest Clinics, Department of Gynecology, Alkmaar, Netherlands PubMed articles Google scholar articles
V Van der Noort Netherlands Cancer Institute, Department of Statistics, Amsterdam, Netherlands PubMed articles Google scholar articles
F Amant Netherlands Cancer Institute, Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands PubMed articles Google scholar articles
D Van den Broek Netherlands Cancer Institute, Department of Clinical Chemistry, Amsterdam, Netherlands PubMed articles Google scholar articles
C Lok Netherlands Cancer Institute, Center for Gynecologic Oncology Amsterdam, Amsterdam, Netherlands PubMed articles Google scholar articles

Citation

Lof P, Van de Vrie R, Korse T, et al

1069 Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with a pelvic mass to an oncology center?

International Journal of Gynecologic Cancer 2021;31:A70-A71.

Publication history

First published October 12, 2021.

Online issue publication

January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.